We evaluated our approach using 10-fold cross-validation and found that our model exhibits significant power (Table 1) for predicting both synergy (AUC = 0.8663, Accuracy = 0.8213) and genotype-selective efficacy (AUC = 0.8809, Accuracy = 0.8230) in context of BRAF melanomas (Fig 1B). The gene discussed is BRAF; the disease is melanoma.